- Home
- RERE vs ARVN Comparison
RERE vs ARVN Comparison
Compare RERE & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | ARVN |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 859.3M | 781.0M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RERE | ARVN |
|---|---|---|
| Price | $5.77 | $12.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 23 |
| Target Price | N/A | ★ $18.14 |
| AVG Volume (30 Days) | ★ 1.6M | 778.2K |
| Earning Date | 03-10-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $2,759,212,837.00 | $312,300,000.00 |
| Revenue This Year | $30.64 | $11.17 |
| Revenue Next Year | $24.84 | N/A |
| P/E Ratio | $35.18 | ★ N/A |
| Revenue Growth | 27.95 | ★ 93.86 |
| 52 Week Low | $2.00 | $5.90 |
| 52 Week High | $6.47 | $20.38 |
Technical Indicators
Market Signals| Indicator | RERE | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 56.01 | 53.70 |
| Support Level | $5.21 | $11.88 |
| Resistance Level | $6.47 | $12.79 |
| Average True Range (ATR) | 0.27 | 0.53 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 47.33 | 68.02 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.